Generic competition · all medicines · read 12 November 2026

Is there a generic of Glecaprevir; Pibrentasvir, and who makes it?

Glecaprevir; Pibrentasvir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.

Glecaprevir; Pibrentasvir2 dosage-form groups in the Orange Book

0generic makers listed

Glecaprevir; Pibrentasvir appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Pellets, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Mavyret. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

10 June 2028Exclusivity I-967 Mavyret
10 June 2028Exclusivity ODE-372 Mavyret
10 December 2028Exclusivity PED Mavyret
10 June 2030Patent 10039754
10 June 2030Patent 10028937
6 November 2030Patent 9586978
10 December 2030Patent 10028937*PED
10 December 2030Patent 10039754*PED
6 May 2031Patent 9586978*PED
19 January 2032Patent 8648037 drug substance
18 May 2032Patent 8937150 drug substance

8 more patents are listed.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Mavyret. No generic is listed as marketed.

generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

10 June 2028Exclusivity I-967 Mavyret
10 June 2028Exclusivity ODE-372 Mavyret
10 December 2028Exclusivity PED Mavyret
10 June 2030Patent 10039754
10 June 2030Patent 10028937
6 November 2030Patent 9586978
10 December 2030Patent 10028937*PED
10 December 2030Patent 10039754*PED
6 May 2031Patent 9586978*PED
19 January 2032Patent 8648037 drug substance
18 May 2032Patent 8937150 drug substance

12 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.